These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 11113711)

  • 1. Thromboembolism in heart failure: who should be treated?
    Diet F; Erdmann E
    Eur J Heart Fail; 2000 Dec; 2(4):355-63. PubMed ID: 11113711
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacological prevention of thromboembolism in patients with left ventricular dysfunction.
    Thatai D; Ahooja V; Pullicino PM
    Am J Cardiovasc Drugs; 2006; 6(1):41-9. PubMed ID: 16489847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Management of heart failure. IV. Anticoagulation for patients with heart failure due to left ventricular systolic dysfunction.
    Baker DW; Wright RF
    JAMA; 1994 Nov 23-30; 272(20):1614-8. PubMed ID: 7966873
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Antiplatelet and anticoagulant therapy in the prevention of thromboemboli in chronic heart failure.
    Garg RK; Gheorghiade M; Jafri SM
    Prog Cardiovasc Dis; 1998; 41(3):225-36. PubMed ID: 9872608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anticoagulation and heart failure.
    Graham SP
    Curr Cardiol Rep; 2001 Jan; 3(1):72-7. PubMed ID: 11139802
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Anticoagulation in chronic heart failure and left ventricular dysfunction].
    Wichter T; Breithardt G
    Dtsch Med Wochenschr; 2002 Oct; 127(41):2145-8. PubMed ID: 12397561
    [No Abstract]   [Full Text] [Related]  

  • 7. Relationship between degree of left ventricular dysfunction, symptom status, and risk of embolic events in patients with atrial fibrillation and heart failure.
    Sandhu RK; Hohnloser SH; Pfeffer MA; Yuan F; Hart RG; Yusuf S; Connolly SJ; McAlister FA; Healey JS
    Stroke; 2015 Mar; 46(3):667-72. PubMed ID: 25628308
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Anticoagulant therapy in left ventricular non-compaction: when, how and why].
    Costantino J; Maria Ajmone F; Maggio E; Ballatore F; Manguso G; Ciaramella P; Galea N; Alfarano M; Severino P; Lavalle C; Vizza CD; Chimenti C
    G Ital Cardiol (Rome); 2023 Nov; 24(11):866-871. PubMed ID: 37901977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antithrombotics in heart failure with reduced ejection fraction and normal sinus rhythm: an evidence appraisal.
    Prom R; Usedom JE; Dull RB
    Ann Pharmacother; 2014 Feb; 48(2):226-37. PubMed ID: 24259641
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anticoagulation in patients with left ventricular systolic dysfunction and sinus rhythm: when?
    Sivri N; Yetkin E; Tekin GO; Yalta K; Waltenberger J
    Clin Appl Thromb Hemost; 2014 Oct; 20(7):729-34. PubMed ID: 23615290
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Anticoagulation in primary prevention of thromboembolism in advanced left ventricular dysfunction].
    Siaplaouras S; Heisel A; Buob A; Jung J
    Med Klin (Munich); 2001 May; 96(5):281-6. PubMed ID: 11395992
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What do we know about anticoagulation in patients with heart failure?
    Ahnert AM; Freudenberger RS
    Curr Opin Cardiol; 2008 May; 23(3):228-32. PubMed ID: 18382211
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thromboembolism and antithrombotic therapy in congestive heart failure.
    Dunkman WB
    J Cardiovasc Risk; 1995 Apr; 2(2):107-17. PubMed ID: 7606647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Aspirin, oral anticoagulants, and heart failure].
    Gibelin P
    Arch Mal Coeur Vaiss; 1998 Nov; 91(11):1377-81. PubMed ID: 9864607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From left ventricular dysfunction to heart failure.
    Cleland JG
    Arch Mal Coeur Vaiss; 1996 Nov; 89(11):1397-402. PubMed ID: 9092398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials.
    Proietti M; Lip GY
    Am J Med; 2016 Oct; 129(10):1110-6. PubMed ID: 27086494
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Study of combined anticoagulant (fluindione)-aspirin therapy in patients with atrial fibrillation at high risk for thromboembolic complications. A randomized trial (FFAACS)].
    Lechat P; Lardoux H; Mallet A; Sanchez P; Derumeaux G; Lecompte T; Maillard L; Mas JL; Mentré F; Pousset F; Lacomblez L; Pisica G; Solbes-Latourette S; Raynaud P; Chaumet-Riffaud P;
    Therapie; 2000; 55(6):681-9. PubMed ID: 11234463
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Thromboembolism and antithrombotic therapy for heart failure in sinus rhythm: an executive summary of a joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis.
    Lip GY; Piotrponikowski P; Andreotti F; Anker SD; Filippatos G; Homma S; Morais J; Pullicino P; Rasmussen LH; Marín F; Lane DA;
    Thromb Haemost; 2012 Dec; 108(6):1009-22. PubMed ID: 23093044
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Anticoagulant therapy in patients with dilated cardiomyopathy].
    Gensini GF; Rostagno C
    Ann Ital Med Int; 1998; 13(4):227-32. PubMed ID: 10349204
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antithrombotic therapy for heart failure in sinus rhythm.
    Subramaniam V; Davis RC; Shantsila E; Lip GY
    Fundam Clin Pharmacol; 2009 Dec; 23(6):705-17. PubMed ID: 19735305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.